AVIS PHARMALABS EXIM PRIVATE LIMITED |
Registered number: |
13079984 |
Balance Sheet |
as at 30 November 2021 |
|
Notes |
|
|
2021 |
|
£ |
|
Current assets |
Cash at bank and in hand |
|
|
760 |
|
Creditors: amounts falling due within one year |
3 |
|
(997) |
|
Net current liabilities |
|
|
|
(237) |
|
|
Net liabilities |
|
|
|
(237) |
|
|
|
|
|
|
|
Capital and reserves |
Share premium |
|
|
|
3 |
Profit and loss account |
|
|
|
(240) |
|
Shareholders' funds |
|
|
|
(237) |
|
|
|
|
|
|
|
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
The members have not required the company to obtain an audit in accordance with section 476 of the Act. |
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
V. PUROHIT |
Director |
Approved by the board on 29 August 2022 |
|
AVIS PHARMALABS EXIM PRIVATE LIMITED |
Notes to the Accounts |
for the period from 14 December 2020 to 30 November 2021 |
|
|
1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Going concern |
|
On March 2020, the World Health Organisation formally recognised COVID-19 as a pandemic. The implications of COVID-19 resulted in many governments across the world deciding to close down non-essential operations, which will have a great impact on the global economy. At the date of approving the financial statements, due to the corrective action taken to reduce expenses and preserve cash, the pandemic has not resulted in a significant impact to the Company's access to liquidity to manage operations on an ongoing basis. Additionally the director has provided assurance that they will continue to support the company to enable it to meet its liabilities as they fall due.On the basis, the accounts have been prepared on going concern basis. |
|
|
Creditors |
|
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. |
|
|
2 |
Employees |
2021 |
|
Number |
|
|
|
Average number of persons employed by the company |
3 |
|
|
|
|
|
|
|
|
|
3 |
Creditors: amounts falling due within one year |
2021 |
|
£ |
|
|
|
Bank loans and overdrafts |
997 |
|
Other creditors |
- |
|
|
|
|
|
|
997 |
|
|
|
|
|
|
|
|
|
|
4 |
Other information |
|
|
AVIS PHARMALABS EXIM PRIVATE LIMITED is a private company limited by shares and incorporated in England. Its registered office is: |
|
9, Lassell Gardens |
|
Maidenhead |
|
England |
|
SL6 8ND |